An additional analysis of data collected during the Phase 3 PARADIGMS trial found Gilenya (fingolimod) can prevent the progression of disability and control multiple sclerosis (MS) activity in pediatric patients. Results of the analysis were the subject of an oral presentation Tuesday at the 2018 American Academy of Neurology (AAN) Annual Meeting in Los Angeles. The presentation was titled … Continue reading #AAN2018 – Review of Phase 3 Trial Data Supports Gilenya as Treatment for Pediatric MS